> Mersana said Thursday that the FDA had issued a partial clinical hold after five study participants had fatal bleeding events, a rate that was higher than wou

> Mersana said Thursday that the FDA had issued a partial clinical hold after five study participants had fatal bleeding events, a rate that was higher than would have been expected. About 560 people have taken the study drug to date, the company said. Because if you write "0.5% deaths with unexpected circumstances triggered FDA to do what it should do" wouldn't be so clickbaity.